Kenyan Health Patient Information Leaflet
Non-opioid analgesic / antipyretic
Inflammation and pain in rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. Clinical selection for Serratiopeptidase /Aceclofenac / Paracetamol should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC. Class context: Non-opioid analgesic / antipyretic. Confirm site-specific dose, duration and monitoring before prescribing.
Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.
[Serratiopeptidase] [From component Diclofenac] GIT disturbances, GIT ulceration, headache, dizziness, vertigo, tinnitus, taste alteration, blood dyscrasia, renal, hepatic disorders. [Aceclofenac] Dyspepsia, nausea, fluid retention, raised BP. Serious: peptic ulcer/bleed, AKI, heart failure exacerbation, severe skin reactions, bronchospasm, hepatitis (rare). [Paracetamol] Rare at therapeutic doses. Serious: acute liver failure in overdose, rare severe skin reactions (SJS/TEN/AGEP).
Store as labelled. Keep out of reach of children.